Rui Tato Marinho (MD, PhD)
Director Clínico/Medical Director Centro Hospitalar Universitário Lisboa Norte (Hospital Santa Maria/Hospital Pulido Valente)
Diretor National Program for Viral Hepatitis
Me!

5 kms

Several NGOs
Hepatitis NANB going C?

THE LANCET, AUGUST 3, 1974

LONG-INCUBATION POST-TRANSFUSION
HEPATITIS WITHOUT SEROLOGICAL
EVIDENCE OF EXPOSURE TO HEpatitis-B
Virus

Alfred M. Prince          Betsy Brotman
George F. Grady           William J. Kuhns
Charles Hazzi             Richard W. Levine
Stephen J. Millian

Laboratory of Virology, New York Blood Center;
State Laboratory Institute, Massachusetts Department of
Public Health, Boston; Departments of Pathology and
Medicine, New York University School of Medicine; and
Virus Laboratory, New York City Department of Health

Our findings imply that a substantial proportion of
post-transfusion hepatitis cases is caused neither by
HB virus nor hepatitis A agent, and suggest the existence of an additional virus(es), hepatitis type C.
INFECÇÕES VÍRICAS EM TOXICODEPENDENTES DE DROGAS ENDOVENOSAS. Significado Clínico e Prognóstico

HELENA GLÓRIA, F. RAMALHO, R. MARINHO, MARÍLIA PEDRO, J. VELOSA, M. CARNEIRO MOURA

QUADRO 2 — Prevalência global de marcadores para o VHB, VHD, VHC e HIV1

<table>
<thead>
<tr>
<th></th>
<th>N.º casos</th>
<th>N.º casos positivos</th>
</tr>
</thead>
<tbody>
<tr>
<td>AgHBs</td>
<td>131</td>
<td>28</td>
</tr>
<tr>
<td>VHB</td>
<td>121</td>
<td>28</td>
</tr>
<tr>
<td>VHD</td>
<td>110</td>
<td>28</td>
</tr>
<tr>
<td>VHC</td>
<td>100</td>
<td>83</td>
</tr>
<tr>
<td>HIV1</td>
<td>120</td>
<td>1</td>
</tr>
</tbody>
</table>

QUADRO 1 — Dados epidemiológicos em 135 toxicodependentes de drogas endovenosas

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>N.º</td>
<td>135</td>
<td></td>
</tr>
<tr>
<td>Homens</td>
<td>107</td>
<td></td>
</tr>
<tr>
<td>Mulheres</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>Índice H/M</td>
<td>3.81</td>
<td></td>
</tr>
<tr>
<td>Idade média (anos)</td>
<td>25±4</td>
<td></td>
</tr>
</tbody>
</table>

1991 - Data in PWID!!
This is Liver
The threat to public health of hepatitis C.

Levanchy D.

Author information

WHO, Division of Emerging and other Communicable Diseases Surveillance and Control, Geneva, Switzerland.

80% PWID

1989

1991

U. CE. Hepatologia

1997

HCV 3% world

2001

FibroScan

2005

2010

2014

Lisbon

Plan Nacional para a Hepatite C

Journal of Gastroenterology and Hepatology

City University Hospital, Lisbon

96%

Almost Free for all, NHS Decriminalization
1. Overall efficiency in all WHO member states

<table>
<thead>
<tr>
<th>Rank</th>
<th>Uncertainty Interval</th>
<th>Member State</th>
<th>Index</th>
<th>Uncertainty Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1 - 5</td>
<td>France</td>
<td>0.994</td>
<td>0.982 - 1.000</td>
</tr>
<tr>
<td>2</td>
<td>1 - 5</td>
<td>Italy</td>
<td>0.991</td>
<td>0.978 - 1.000</td>
</tr>
<tr>
<td>3</td>
<td>1 - 6</td>
<td>San Marino</td>
<td>0.988</td>
<td>0.973 - 1.000</td>
</tr>
<tr>
<td>4</td>
<td>2 - 7</td>
<td>Andorra</td>
<td>0.982</td>
<td>0.966 - 0.997</td>
</tr>
<tr>
<td>5</td>
<td>3 - 7</td>
<td>Malta</td>
<td>0.978</td>
<td>0.965 - 0.993</td>
</tr>
<tr>
<td>6</td>
<td>2 - 11</td>
<td>Singapore</td>
<td>0.973</td>
<td>0.947 - 0.998</td>
</tr>
<tr>
<td>7</td>
<td>4 - 8</td>
<td>Spain</td>
<td>0.972</td>
<td>0.959 - 0.985</td>
</tr>
<tr>
<td>8</td>
<td>4 - 14</td>
<td>Oman</td>
<td>0.961</td>
<td>0.938 - 0.985</td>
</tr>
<tr>
<td>9</td>
<td>7 - 12</td>
<td>Austria</td>
<td>0.959</td>
<td>0.946 - 0.972</td>
</tr>
<tr>
<td>10</td>
<td>8 - 11</td>
<td>Japan</td>
<td>0.957</td>
<td>0.948 - 0.965</td>
</tr>
<tr>
<td>11</td>
<td>8 - 12</td>
<td>Norway</td>
<td>0.955</td>
<td>0.947 - 0.964</td>
</tr>
<tr>
<td>12</td>
<td>10 - 15</td>
<td>Portugal</td>
<td>0.945</td>
<td>0.931 - 0.958</td>
</tr>
<tr>
<td>13</td>
<td>10 - 15</td>
<td>Monaco</td>
<td>0.940</td>
<td>0.920 - 0.957</td>
</tr>
<tr>
<td>14</td>
<td>13 - 19</td>
<td>Greece</td>
<td>0.933</td>
<td>0.921 - 0.945</td>
</tr>
<tr>
<td>15</td>
<td>12 - 20</td>
<td>Iceland</td>
<td>0.932</td>
<td>0.917 - 0.948</td>
</tr>
<tr>
<td>16</td>
<td>14 - 21</td>
<td>Luxembourg</td>
<td>0.928</td>
<td>0.914 - 0.942</td>
</tr>
<tr>
<td>17</td>
<td>14 - 21</td>
<td>Netherlands</td>
<td>0.928</td>
<td>0.914 - 0.942</td>
</tr>
<tr>
<td>18</td>
<td>16 - 21</td>
<td>United Kingdom</td>
<td>0.925</td>
<td>0.913 - 0.937</td>
</tr>
<tr>
<td>19</td>
<td>14 - 22</td>
<td>Ireland</td>
<td>0.924</td>
<td>0.909 - 0.939</td>
</tr>
<tr>
<td>20</td>
<td>17 - 24</td>
<td>Switzerland</td>
<td>0.916</td>
<td>0.903 - 0.930</td>
</tr>
</tbody>
</table>
CASE STUDY

DRUG DECRIMINALISATION IN PORTUGAL: SETTING THE RECORD STRAIGHT

KEY POINTS

- Drug-related deaths fell after the reform of Portugal's drug policy, and have remained below the EU average since 2001.
- The proportion of the prison population sentenced for drug offences has fallen from over 40% to 15%.
- Rates of drug use have remained consistently below the EU average.
- Portugal has gone from accounting for over 50% of yearly HIV diagnoses linked to injecting drug use in the EU to 1.7%.
NEW HIV DIAGNOSES ATTRIBUTED TO INJECTING DRUG USE

Data: ECDC\textsuperscript{40}
1998 … THE PROBLEMS … TODAY

- 16% Heroin users
- 0.33% Population
- 3% HIV new cases
- 2% IV Route
- 33 200 Problematic users
- 63 Overdoses deaths
Drug overdose

Number of deaths per million people, latest available data

Scotland
Estonia
Sweden
Norway
United Kingdom
Ireland
Denmark
Finland
Lithuania
Slovenia
Austria
Cyprus
Croatia
European Union
Netherlands
Germany
Luxembourg
Latvia
Turkey
Malta
Spain
Belgium
Italy
France
Poland
Czech Republic
Hungary
Slovakia
Bulgaria
Portugal
Romania

Source: National Records of Scotland. Note: No data available for Greece.
Top – Five Stars

1. National Health System, Free Health for All (1979), the 12th most efficient by WHO (2000)
2. Annual Meeting European Association Study Liver (EASL), Lisbon (1981)
5. Liver Units, outpatient Consultation for Hepatology (1989)
6. Very active civil society (NGOs, 1990)
   Liga Portuguesa Contra SIDA, Abraço, Sol, Associação Positivo
7. Risk reduction (OST, NSP 1990)
8. Liver transplant (1992)
11. 33rd Annual Meeting EASL, Lisbon (1998)
13. Hepatitis B vaccine, birth dose at Hospital for all newborns (2000)
15. Elastography (Fibroscan) (2005)
   Plus imagiology, surgery, liver transplant,
17. HCV clinical trials for DAA, with publications in NEJM (2013)
22. Task-Force for severe acute hepatitis in children (2022)
23. Portugal as a founding member – United Nations Group of Friends for Viral Hepatitis (2022)
24. World Hepatitis Alliance/WHO in Lisbon, 9-11 April, Portugal, 2024
Point of Care
Going Local
Portuguese Parliament
Mr. President
Hospital Going To Prison

E. P. Lisboa

~1000 pop

1.9 km from Hospital
Going to Prisons
Consumption Rooms
Homeless
report tallied the costs against the benefits of relief for the homeless (including free shelter, assistance programs, free heroin, and prevention services) and concluded that investing in a street sleeper offers the highest return on investments around. Every euro invested in fighting homelessness in the Netherlands enjoys returns in savings on social services, police costs. 3

“Relief is preferable and less expensive on the street,” the researchers concluded. Their calculations only looked at the savings for government of course eliminating the problem of homelessness have payoffs for a city’s businesses and residents.

Relief for the homeless, in short, is a win-win-win-win policy.
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

Stefan Zeuzem, M.D., Ira M. Jacobson, M.D., Tolga Baykal, M.D., Rui T. Marinho, M.D., Ph.D., Fred Poordad, M.D., Marc Bourlière, M.D., Mark S. Sulkowski, M.D., Heiner Wedemeyer, M.D., Edward Tam, M.D., Paul Desmond, M.D., Donald M. Jensen, M.D., Adrian M. Di Bisceglie, M.D., Peter Varunok, M.D., Tarek Hassanein, M.D., Junyuan Xiong, M.D., Tami Pilot-Matias, Ph.D., Barbara DaSilva-Tillmann, M.D., Lois Larse, M.D., Thomas Podsadecki, M.D., and Barry Bernstein, M.D.

ABSTRACT

BACKGROUND

In this phase 3 trial we evaluated the efficacy and safety of the integrase combination of ABT-450 with ritonavir (ABT-450/r), ombitasvir (also known as ABT-267), dasabuvir (also known as ABT-333), and ribavirin for the retreatment of HCV in patients who were previously treated with peginterferon–ribavirin.

![Figure 1. Sustained Virologic Response in the Entire Active-Regimen Group and According to Hepatitis C Virus (HCV) Genotype.](image-url)
Once in Life

Key Ideas
The Roadmap – Humanism and Dignity

- Political will, legislation
- National Organization for Drug Addiction (SICAD; DICAD)
- No stigma, all are humans
- Restaurative Justice
- The fantastic NGOs
- Drugs are public health (mental), not only criminal
- All together, total package
- Needle Syringe Programs (global kit)
- Opioid Agonist Maintenance Therapy
- Hospital on road and streets
- Etc, etc
Figure 6. Targets for reducing new cases of and deaths from chronic viral hepatitis B and C infection

- **VHB** – 40,000
- **VHC** – 30,000
2020
Hepatite C
Alter
Houghton
Rice
Cura
Salvaram muitas Vidas
Figure 6. Targets for reducing new cases of and deaths from chronic viral hepatitis B and C infection.
HSM>EPL
Consultation, Blood, Fibroscan
### Principais causas de morte e percentagem de variação da taxa de mortalidade padronizada pela idade (<75 anos) em Portugal, idade prematura, ambos os sexos, 2007-2009 e 2016-2018

<table>
<thead>
<tr>
<th>Causa</th>
<th>TMP 75</th>
<th>% Variação</th>
</tr>
</thead>
<tbody>
<tr>
<td>TM laringe, traqueia, brônquios e pulmões</td>
<td>29.1</td>
<td>4.3%</td>
</tr>
<tr>
<td>Doenças isquêmicas do coração</td>
<td>24.7</td>
<td>-6.8%</td>
</tr>
<tr>
<td>Doenças cérébro-vasculares</td>
<td>20.3</td>
<td>-38.5%</td>
</tr>
<tr>
<td>TM estômago</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TM cólon</td>
<td>10.7</td>
<td>-15.7%</td>
</tr>
<tr>
<td>Outras doenças cardíacas</td>
<td>10.5</td>
<td>2.9%</td>
</tr>
<tr>
<td>TM tecido linfático e hematopoético</td>
<td>10.2</td>
<td>-3.8%</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>9.2</td>
<td>-35.7%</td>
</tr>
<tr>
<td>TM mama</td>
<td>9.7</td>
<td>-9.3%</td>
</tr>
<tr>
<td>Outras doenças cardíacas</td>
<td>10.5</td>
<td>2.9%</td>
</tr>
<tr>
<td>VIH/sida</td>
<td>7.2</td>
<td>-20.0%</td>
</tr>
<tr>
<td>Doenças crônicas vias aéreas inferiores</td>
<td>6.2</td>
<td>6.9%</td>
</tr>
<tr>
<td>TM pâncreas</td>
<td>7.9</td>
<td>21.5%</td>
</tr>
<tr>
<td>Suicídios</td>
<td>7.8</td>
<td>-2.5%</td>
</tr>
<tr>
<td>VIH/sida</td>
<td>2.9</td>
<td>-58.6%</td>
</tr>
</tbody>
</table>

**Cirrhosis**

- **2021-2030 National Health Plan**
- **14.3 Diabetes mellitus**
- **13.8 TM estômago**
- **12.7 TM cólon**
- **10.7 TM mama**
- **10.6 TM tecido linfático e hematopoético**
- **10.2 Outras doenças cardíacas**
- **9.4 Acidentes de transporte**
- **9.0 Pneumonia**
- **8.0 Suicídios**
- **7.0 VIH/sida**
- **6.7 Doenças crônicas vias aéreas inferiores**
- **6.5 TM pâncreas**
- **5.8 TM lábio, cavidade bucal e faringe**

- **Liver Cancer**

- **Liver**

**Fonte:** INE. Tratamento de d
Lisbon, near me

URBAN INTERVENTION PLAN OF CASAL VENTOSO

1998-2000 (N=558)

- HIV: 61%
- HCV: 79%
- TP: 14%
- PWID: 95%
- No Treatment Before: 90%